Project Grant R43AG059277

The U.S. National Heart, Lung, and Blood Institute (NHLBI) awarded a 2-year, $225,600 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Colorado-Denver to engineer a lab-on-a-particle platform for measuring platelet function. The objective is to design elastic hydrogel microparticles that can quantify key platelet characteristics such as adhesion, activation, aggregation, and contraction through both kinetic and equilibrium-based assays. This...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $552,413 to Thomas Jefferson University (Sidney Kimmel Medical College) for a research project titled "Short Inhibitory RNAs in Platelet and Megakaryocyte Function." The key objectives are to: 1) investigate in vivo knockdown of the P2Y12 receptor in megakaryocytes and platelets as a potential antithrombotic...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $657,368 to The Washington University in St. Louis to investigate the regulation of microRNA (miRNA) decay during hematopoietic stem cell development. The research aims to decipher the molecular pathways controlling post-transcriptional regulation and degradation of miRNAs, which are essential for proper blood cell formation. The...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $542,442 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Emory University to develop and validate a new diagnostic technology called MCATS (Mechano-Assisted CAS12A Tension Sensor) for rapid detection of heparin-induced thrombocytopenia (HIT). The project aims to investigate the link between HIT activation and platelet mechanical forces, optimize the MCATS technology to enhance signal detection...

This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) provides $432,834 to the Board of Regents of the University of Nebraska to develop an "enzyme-free, label-free quantitative microarray technology" for profiling mixtures of approximately 25 microRNA (miRNA) sequences. The goal is to create a "perfect switch" binary probe design that generates a redox signal upon target...

This $554,653 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of "RARECYTEFINDER", a label-free, genome-wide copy number-based method for the unbiased identification and comprehensive molecular analysis of rare disseminated tumor cells (DTCs) in liquid and tissue biopsies. The key objectives of this 4-year project are to: 1) advance and validate the RARECYTEFINDER...

This Project Grant award from the National Human Genome Research Institute (NHGRI), under the Human Genome Research federal grant program (CFDA 93.172), provides $249,000.00 to The General Hospital Corporation (Massachusetts General Hospital) to conduct a multi-omic investigation of clonal hematopoiesis and associated diseases. The key objectives are to: 1) develop a statistical method to improve discovery and translational insights from proteomics data; 2) examine how the presence of clonal...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,095,816 Project Grant under CFDA 93.837 (Cardiovascular Diseases Research) to The DNA Medicine Institute, Inc. to develop a 5-minute point-of-care test that can rapidly measure anti-Factor Xa activity and hemoglobin levels. This device is intended to guide emergency management of patients on direct oral anticoagulants, enabling quicker delivery of life-saving interventions during bleeding events or strokes. The project will...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $400,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Electronic Biosciences, Inc. (EBS), a small biotechnology company based in San Diego, California. The grant supports the development of a novel analytical device to precisely characterize lipoprotein particles in blood. Lipoproteins are a key indicator of cardiovascular disease risk, as certain classes contribute to the buildup of plaque in...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $267,310 to Weill Medical College of Cornell University to identify tumor antigens derived from mis-spliced mRNAs caused by spliceosomal mutations in myelodysplastic syndromes (MDS) and develop T-cell receptor (TCR) therapeutics to target them. The key objectives are to: 1) predict and validate tumor antigens from analysis of...